Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion

Immunity
Nicole MalandroJedd D Wolchok

Abstract

Current approaches to cancer immunotherapy aim to engage the natural T cell response against tumors. One limitation is the elimination of self-antigen-specific T cells from the immune repertoire. Using a system in which precursor frequency can be manipulated in a murine melanoma model, we demonstrated that the clonal abundance of CD4(+) T cells specific for self-tumor antigen positively correlated with antitumor efficacy. At elevated precursor frequencies, intraclonal competition impaired initial activation and overall expansion of the tumor-specific CD4(+) T cell population. However, through clonally derived help, this population acquired a polyfunctional effector phenotype and antitumor immunity was enhanced. Conversely, development of effector function was attenuated at low precursor frequencies due to irreversible T cell exhaustion. Our findings assert that the differential effects of T cell clonal abundance on phenotypic outcome should be considered during the design of adoptive T cell therapies, including use of engineered T cells.

References

Apr 1, 1993·The Journal of Experimental Medicine·E A Ranheim, T J Kipps
Jul 1, 1994·The Journal of Experimental Medicine·A N Houghton
Dec 22, 1998·The Journal of Experimental Medicine·A J ZajacR Ahmed
Oct 18, 2000·The Journal of Experimental Medicine·R M KedlP Marrack
Mar 6, 2002·The Journal of Experimental Medicine·Joseph N BlattmanRafi Ahmed
Oct 17, 1959·British Medical Journal·M BURNET
Aug 3, 2004·Nature Reviews. Immunology·Michael J Bevan
Jul 19, 2005·Nature Immunology·Amanda L MarzoLeo Lefrançois
Mar 4, 2006·Science·Jason HatayeMarc K Jenkins
Aug 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Richard A WillisPhilippa C Marrack
Sep 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·David A Blair, Leo Lefrançois
Mar 21, 2008·Blood·Pawel MuranskiNicholas P Restifo
Apr 1, 2009·The Journal of Experimental Medicine·Gabrielle A RizzutoAlan N Houghton
Feb 17, 2010·The Journal of Experimental Medicine·Ying XiePaul Andrew Antony
Feb 5, 2011·Proceedings of the National Academy of Sciences of the United States of America·Juan QuielWilliam E Paul
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll

❮ Previous
Next ❯

Citations

Apr 1, 2018·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stephen R GodingPaul Andrew Antony
Dec 20, 2017·Frontiers in Immunology·Chansavath PhetsouphanhJohn J Zaunders
Jan 16, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tara S AbrahamAdam E Snook
Jun 9, 2017·Science Translational Medicine·Emma NolanGeoffrey J Lindeman
May 18, 2016·Proceedings of the National Academy of Sciences of the United States of America·Hidetoshi NakagawaHye-Jung Kim
May 18, 2018·JCI Insight·Dongrui WangChristine E Brown
Jan 11, 2018·Scientific Reports·Hiroshi NakashimaE Antonio Chiocca
Mar 18, 2021·Journal of the Royal Society, Interface·Sam PalmerRuairí Donnelly
Sep 24, 2021·PLoS Pathogens·Hannah KaminskiThomas Pradeu
Jun 16, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexandra M MiggelbrinkPeter E Fecci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.

Related Papers

Cancer Chemotherapy and Biological Response Modifiers
Qiangzhong MaRichard P Junghans
[Rinshō ketsueki] The Japanese journal of clinical hematology
Hiroaki IkedaHiroshi Shiku
Discovery Medicine
Terrence L Geiger, Jeffrey E Rubnitz
© 2022 Meta ULC. All rights reserved